RE:RE:RE:New poster on liver inflammation at EndoMaybe the could pre announce it or maybe not, but they can always follow it up with a CC and try to explain the significance of all these small details in plan English so investors understand every little extra value these findings add to the overall process. If you go on other chat rooms most already shareholders of the company don't have a clue what all these abstracts mean what they do understand is the balance of their investment account.
They need to explain their science and potential future financial opportunity it offers if successful, anything/everything which contributes to higher success rate needs to be explained and understood by retail investors so they stay invested and new investors jump on the opportunity to make a good return.
SPCEO1 wrote: I believe there is a note at the end of the link in the press release where the folks that run the ENDO conference require companies to not divulge anything about their session until 11AM the day t he conferencec started. I have to believe they could have at least said they would be presenting a paper there earlier, but maybe even that is not allowed.
ANALIAS00 wrote: Light question ...
Who knew about the "Endocrine Societys annual meeting, ENDO 2021" ?
Why important enought to send a PR after that meeting and not enought to send a PR announcing that they would be attending that meeting ?
Is it just normal in the industry or part of a strategy ?
jfm1330 wrote: Strange to publish that on a friday night.
https://www.abstractsonline.com/pp8/#!/9188/presentation/2240
https://www.theratech.com/theratechnologies-announces-new-data-demonstrating-tesamorelins-positive-effect-on-immune-response-linked-to-liver-inflammation/